Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
Paul E Oberstein, J Randolph Hecht, Kanwal Raghav...
https://pubmed.ncbi.nlm.nih.gov/42013403/Actively Recruiting
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
225
Participants Needed
53
Research Sites
210 weeks
Total Duration
Researchers are evaluating the anti-tumor activity and safety of amivantamab, alone and combined with standard chemotherapy, in participants with advanced or metastatic colorectal cancer. This study focuses on different groups based on prior treatments and tumor characteristics, aiming to find effective dosing for amivantamab combined with standard chemotherapy. The study includes participants with specific genetic tumor profiles and performance status, assessing treatment effects in various cohorts. Participants receive intravenous infusions of amivantamab alone or with chemotherapy regimens such as mFOLFOX6 or FOLFIRI, depending on their cohort and prior treatment history. The treatment cycles last 28 days and continue until the end of treatment visit, which occurs up to 30 days after discontinuation. Dose levels and schedules vary by cohort, with some receiving monotherapy and others combination therapies at doses determined in earlier phases. Throughout the study, participants undergo physical exams, performance status assessments, laboratory tests, vital sign monitoring, and adverse event tracking. Tumor response and disease control are measured using standard criteria over up to four years and three months. Biopsies are required for certain cohorts to assess tumor characteristics. Safety and treatment effects are closely monitored during and after treatment to evaluate amivantamabs impact.
CONDITIONS
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
S
Study Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Janssen Research & Development, LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Amivantamab alone | Amivantamab with FOLFOX or FOLFIRI | Standard FOLFOX/FOLFIRI (± biologics) |
|---|---|---|---|
| What it is | Amivantamab given alone to patients with RAS/BRAF/EGFR wild‑type metastatic colorectal cancer in separate cohorts | Amivantamab combined with mFOLFOX6 or FOLFIRI chemotherapy in other trial cohorts | Standard first‑line chemotherapy backbone for RAS/BRAF wild‑type metastatic colorectal cancer, often FOLFOX or FOLFIRI with or without biologics |
| Role in trial | Investigational single‑agent arm | Investigational combination therapy arms | Represents current usual-care chemotherapy options outside trial |
| Primary use | To assess the activity of single‑agent Amivantamab in chemorefractory mCRC | To evaluate safety and antitumor activity of Amivantamab combined with chemotherapy | Used as first‑line chemotherapy backbone for metastatic colorectal cancer |
| Administration | Intravenous Amivantamab given alone in separate cohorts | Intravenous Amivantamab infused together with standard mFOLFOX6 or FOLFIRI chemotherapy regimens | Intravenous fluoropyrimidine‑based regimens with oxaliplatin or irinotecan, often with biologic agents |
| Evidence status | Phase Ib/II activity shows response rates around 19–29% in chemorefractory RAS/BRAF wild‑type mCRC | Combination with mFOLFOX6/FOLFIRI showed higher response rates (~51%) and median PFS ~9.2 months in early data | FOLFOX or FOLFIRI regimens with biologics provide established first‑line disease control in RAS/BRAF wild‑type mCRC |
| Key risks | Reported grade ≥3 events include rash, dermatitis acneiform, hypoalbuminemia, with occasional discontinuation | Safety consistent with individual components; detailed safety profile under evaluation | Known toxicities with FOLFOX or FOLFIRI (e.g., neuropathy, myelosuppression) typically characterized in guidelines |
| Limitations | Single‑agent cohort in later‑line patients; small sample sizes and single‑arm design limit comparison | Early phase data without randomized comparison to standard regimens; longer follow‑up pending | Efficacy established but may be less active in refractory and mutation‑specific subsets |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 28 days
Participants are screened for eligibility to participate in the trial.
Duration - 28-day cycles continuing until end of treatment visit, up to 30 days after stopping study drugs
Participants receive intravenous infusions of amivantamab alone or combined with standard chemotherapy regimens like mFOLFOX6 or FOLFIRI according to their cohort and prior treatment history.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Paul E Oberstein, J Randolph Hecht, Kanwal Raghav...
https://pubmed.ncbi.nlm.nih.gov/42013403/Janssen Research & Development, LLC
Lead Sponsor